ENTRAYNIA

What this means for you

Not registered yet, but its 22 Oct 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99457144

Mark type

Stylized text

Filed

22 Oct 2025

Published for opposition

13 Jan 2026

Attorney of record

Jayme M. Torelli

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment of fatigue; Pharmaceutical preparations for the treatment of narcolepsy; Pharmaceutical preparations for the treatment of levodopa-induced dyskinesias in Parkinson's Disease; Pharmaceutical preparations for the treatment of viral pneumonia; Pharmaceutical preparations for the treatment of social anxiety disorder and social anxiety disorder performance-only subtype; Pharmaceutical preparations for the treatment of respiratory distress, acute respiratory distress syndrome, and inflammatory lung injury; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations for the reduction of cravings for alcohol, food, nicotine, opioids, or opiates; Pharmaceutical preparations for facilitating emergence from general anesthesia; Pharmaceutical preparations for improving cognition; Pharmaceutical preparations for the treatment of gastric motility and gastric emptying disorders

Owner

• Vanda Pharmaceuticals Inc., Washington, DC, US
• Vanda Pharmaceuticals Inc., Washington, DC, US

Prosecution history

• 26 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 25 Mar 2026 — SOU EXTENSION 1 GRANTED
• 25 Mar 2026 — SOU EXTENSION 1 FILED
• 25 Mar 2026 — SOU TEAS EXTENSION RECEIVED
• 10 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 13 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 13 Jan 2026 — PUBLISHED FOR OPPOSITION
• 07 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 15 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 10 Dec 2025 — ASSIGNED TO EXAMINER
• 22 Oct 2025 — APPLICATION FILING RECEIPT MAILED
• 22 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 22 Oct 2025 — NEW APPLICATION ENTERED